Yair Reisner
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
 | This article uses bare URLs, which may be threatened by link rot. (June 2022) (Learn how and when to remove this template message) |
| Yair Reisner | |
|---|---|
| File:Yair Reisner.jpgYair_Reisner.jpg Prof. Yair Reisner | |
| Born | 1948 Israel |
| 💼 Occupation | |
| 🏅 Awards | EMET Prize Mortimer M. Borton Award (ASBMT)Rappaport Prize Maharshi Sushruta International Prize Mechtild Harf Prize |
| Twitter= | |
Yair Reisner (born 1948) is Professor emeritus in the department of Immunology at Weizmann Institute of Science, and
Professor in the Department of Hematopoietic Stem Cell Transplantation and Cell Therapy at MD Anderson Cancer Center in Houston, Texas.
Reisner is known for his pioneering studies in developing bone marrow transplantation across major genetic barriers.
Biography[edit]
Reisner was born in Tel Aviv, Israel, and grew up in Ramat Gan. He completed his undergraduate studies in chemistry and psychology at the Hebrew University of Jerusalem in 1972, and an MSc in biochemistry at the University of California at Berkley in 1973. In 1978 he completed his PhD under the supervision of Nathan Sharon in the Department of Biophysics at the Weizmann Institute of Science, He subsequently performed postdoctoral research at the Memorial Sloan Kettering Cancer Institute, in New York as part of the research group of Robert Good, one of the founders of modern immunology. Reisner returned to The Weizmann Institute in 1981[1]
Academic activities[edit]
Reisner is Professor Emeritus in the Department of Immunology at the Weizmann Institute of Science, Rehovot Israel, and Professor in the Department of Hematopoietic Stem Cell Transplantation and cell therapy at the MD Anderson Cancer Center in Houston Texas. Between the years 2005-2014 he served as chairman of the Immunology Department at the Weizmann Institute. In 2005 he was selected as the first president of the Israel Stem Cell Society. Reisner has published more than 230 scientific articles in leading scientific journals. He served on the editorial boards of many journals, and between 2004 and 2009 served as the associate editor of Experimental Hematology. In 2020 he was elected to the Israel Academy of Sciences and Humanities[2]
Scientific work[edit]
In 1980 at the Sloan Kettering Cancer institute, Reisner and Richard O'Reilly demonstrated that it was possible to cure severe combined immune deficiency (SCID) patients (also known as bubble babies) by bone marrow transplantation (BMT) from a mis-matched family member (haploidentical), following T -cell depletion of the donor marrow using lectin separated grafts, an approach developed in his PHD preclinical studies ( PNAS 1978). This was the first successful T cell depleted haploidentical BMT, demonstrating complete prevention of graft-versus-host disease (GVHD) and immune reconstitution with donor-derived immune cells.[3][4]The protocol enabled the cure of a large number of these babies.[5] Following the Chernobyl nuclear disaster in 1986, Reisner was invited to Moscow as part of the effort to treat those exposed to extremely high doses of radiation. Together with Robert Gale and Richard Champlin from the US and local experts, they performed four T cell-depleted haploidentical BMT in patients with no suitable matching donor. Two of them made a complete recovery.[6][7] From the 1980s, Reisner's research concentrated on optimizing protocols to overcome the activity of residual host T cells that survive the pre transplant chemotherapy and radiation used for conditioning in leukemia patients. These T cells can prevent transplant engraftment especially in recipients of T cell depleted BMT. In the mid-1990s he showed that infusion of megadoses of donor-derived T cell-depleted hematopoietic stem cells can overcome this obstacle.[2][8] He showed that the hematopoietic stem cells in the megadose transplants exhibit unique "Veto" activity, able to eliminate host immune cells directed against the graft. He studied this veto activity beginning in the mid 90s and these findings led to a collaboration continuing over decades with Massimo Martelli of Perugia, Italy. Together, they performed more than 300 transplants using unmatched haploidentical marrow, demonstrating that the approaches are effective in preventing not only GVHD but also graft rejection.[9][10][11][12][13]
Reisner is continuing his research investigating the activity of cell populations that contribute to immune tolerance. In particular, he described in detail the activity of Veto T cells, which can specifically block rejection through a mechanism based on Fas-FasL.[14] Furthermore, this cell population can be effectively expanded in culture prior to transplantation.[15][16] Subsequently, he demonstrated that using such veto cells in conjunction with megadose of T cell depleted BMT, can facilitate safer transplants using more gentle conditioning protocols, that are less likely to be associated with infections or other transplant related adverse effects.[17][18] Initial clinical trials are ongoing at MD Anderson Cancer Center in Houston Texas. If successful, this safer haploidentical BMT modality could be attractive for elderly patients with hematological malignancies or with non-malignant diseases such as sickle cell anemia or thalassemia, as well as for a variety of autoimmune diseases. For the past decade, lung stem cell transplantation has become an additional major focus of Reisner's research. Based on insights from bone marrow transplantation he developed strategies to use lung stem cell transplantation by simple intravenous infusion. In particular he demonstrated initially the importance of stem cell competition between host and donor cells.[19][20] and more recently he developed a new strategy for lung stem cell transplantation across major genetic barriers.[21]
Prizes[edit]
- 1996 – Mortimer M. Borton lecture for outstanding Research in Blood and Marrow Transplantation (ASBMT).
- 2002 – Maharshi Sushruta International Prize for Research in Transplantation Biology (Achmadbad India).
- 2003 – Selected by the World Technology Network as one of five researchers in the Medical Sciences
- 2003 – Awarded an Honorary doctorate in medicine from the University of Perugia, Italy.
- 2004 – Awarded the Abisch-Frenkel Prize for Excellence in the Life Sciences.
- 2012 – Samuel and Paula Elekeles Prize for Outstanding Research in the Biomedical Field
- 2013 – European Society of Bone Marrow Transplantation Prize celebrating 30 years of research.
- 2014 – Rappaport lecture for Excellence in Biomedical Research.
- 2015 – Beutler Prize for Research in Genetics.
- 2016 – Jaap de Graeff Medal from the University of Leiden.
- 2018 – Mechtild Harf Prize for Pioneering Studies in Bone Marrow Transplantation, awarded by DKMS, Germany.
- 2019 – EMET Prize for Achievements in the Biological Sciences.
- 2020 – Elected to the Israel Academy of Sciences and Humanities
References[edit]
- ↑ T, Lapidot; A, Terenzi; Ts, Singer; O, Salomon; Y, Reisner (May 15, 1989). "Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts". Blood. 73 (7): 2025–2032. doi:10.1182/blood.V73.7.2025.2025. PMID 2653469 – via pubmed.ncbi.nlm.nih.gov.
- ↑ 2.0 2.1 Lapidot, T.; Terenzi, A.; Singer, T. S.; Salomon, O.; Reisner, Y. (May 15, 1989). "Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts". Blood. 73 (7): 2025–2032. PMID 2653469 – via PubMed.
- ↑ Y, Reisner; N, Kapoor; D, Kirkpatrick; Ms, Pollack; S, Cunningham-Rundles; B, Dupont; Mz, Hodes; Ra, Good; Rj, O'Reilly (February 1, 1983). "Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells". Blood. 61 (2): 341–348. doi:10.1182/blood.V61.2.341.341. PMID 6217853 – via pubmed.ncbi.nlm.nih.gov.
- ↑ Jr, Harold M. Schmeck (February 8, 1983). "BONE MARROW TRANSPLANTS: NEW MEHTHODS MAY SAVE LIVES". The New York Times – via NYTimes.com.
- ↑ Pai, Sung-Yun; Logan, Brent R.; Griffith, Linda M.; Buckley, Rebecca H.; Parrott, Roberta E.; Dvorak, Christopher C.; Kapoor, Neena; Hanson, Imelda C.; Filipovich, Alexandra H.; Jyonouchi, Soma; Sullivan, Kathleen E.; Small, Trudy N.; Burroughs, Lauri; Skoda-Smith, Suzanne; Haight, Ann E.; Grizzle, Audrey; Pulsipher, Michael A.; Chan, Ka Wah; Fuleihan, Ramsay L.; Haddad, Elie; Loechelt, Brett; Aquino, Victor M.; Gillio, Alfred; Davis, Jeffrey; Knutsen, Alan; Smith, Angela R.; Moore, Theodore B.; Schroeder, Marlis L.; Goldman, Frederick D.; Connelly, James A.; Porteus, Matthew H.; Xiang, Qun; Shearer, William T.; Fleisher, Thomas A.; Kohn, Donald B.; Puck, Jennifer M.; Notarangelo, Luigi D.; Cowan, Morton J.; O'Reilly, Richard J. (July 31, 2014). "Transplantation outcomes for severe combined immunodeficiency, 2000-2009". The New England Journal of Medicine. 371 (5): 434–446. doi:10.1056/NEJMoa1401177. PMC 4183064. PMID 25075835.
- ↑ Baranov, Alexandr; Gale, Robert Peter; Guskova, Angelina; Piatkin, Evgeny; Selidovkin, George; Muravyova, Ludmila; Champlin, Richard E.; Danilova, Natalia; Yevseeva, Leonora; Petrosyan, Ludmila; Pushkareva, Svetlana; Konchalovsky, Michail; Gordeeva, Ada; Protasova, Tatiana; Reisner, Yair; Mickey, M. Ray; Terasaki, Paul (January 14, 2010). "Bone Marrow Transplantation after the Chernobyl Nuclear Accident". New England Journal of Medicine. 321 (4): 205–212. doi:10.1056/NEJM198907273210401. PMID 2664512.
- ↑ "Inside the Mission to Perform Bone-Marrow Transplants on Survivors of the Chernobyl Disaster". Time. 24 April 2020.
- ↑ Bachar-Lustig, E.; Rachamim, N.; Li, H. W.; Lan, F.; Reisner, Y. (December 1, 1995). "Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice". Nature Medicine. 1 (12): 1268–1273. doi:10.1038/nm1295-1268. PMID 7489407 – via PubMed. Unknown parameter
|s2cid=ignored (help) - ↑ Aversa, F.; Tabilio, A.; Terenzi, A.; Velardi, A.; Falzetti, F.; Giannoni, C.; Iacucci, R.; Zei, T.; Martelli, M. P.; Gambelunghe, C. (December 1, 1994). "Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum". Blood. 84 (11): 3948–3955. doi:10.1182/blood.V84.11.3948.bloodjournal84113948. PMID 7524753 – via PubMed. Unknown parameter
|s2cid=ignored (help) - ↑ Aversa, Franco; Tabilio, Antonio; Velardi, Andrea; Cunningham, Isabel; Terenzi, Adelmo; Falzetti, Franca; Ruggeri, Loredana; Barbabietola, Giuliana; Aristei, Cynthia; Latini, Paolo; Reisner, Yair; Martelli, Massimo F.; Felicini, Rita; Falcinelli, Flavio; Carotti, Alessandra; Perruccio, Katia; Ballanti, Stelvio; Santucci, Antonella; Gambelunghe, Cesare (October 22, 1998). "Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA Haplotype". New England Journal of Medicine. 339 (17): 1186–1193. doi:10.1056/NEJM199810223391702. PMID 9780338.
- ↑ Reisner, Y.; Martelli, M. F. (September 1, 1995). "Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells". Immunology Today. 16 (9): 437–440. doi:10.1016/0167-5699(95)80021-2. PMID 7546208 – via PubMed.
- ↑ "Study "Offers Patients Hope On Leukemia - New-York Times 1994"". The New York Times.
- ↑ F, Aversa; A, Terenzi; A, Tabilio; F, Falzetti; A, Carotti; S, Ballanti; R, Felicini; F, Falcinelli; A, Velardi; L, Ruggeri; T, Aloisi; Jp, Saab; A, Santucci; K, Perruccio; Mp, Martelli; C, Mecucci; Y, Reisner; Mf, Martelli (May 20, 2005). "Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23 (15): 3447–3454. doi:10.1200/JCO.2005.09.117. PMID 15753458 – via pubmed.ncbi.nlm.nih.gov.
- ↑ Reich-Zeliger, S.; Zhao, Y.; Krauthgamer, R.; Bachar-Lustig, E.; Reisner, Y. (October 1, 2000). "Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite". Immunity. 13 (4): 507–515. doi:10.1016/s1074-7613(00)00050-9. PMID 11070169 – via PubMed.
- ↑ E, Ophir; N, Or-Geva; I, Gurevich; O, Tal; Y, Eidelstein; E, Shezen; R, Margalit; A, Lask; G, Shakhar; D, Hagin; E, Bachar-Lustig; S, Reich-Zeliger; A, Beilhack; R, Negrin; Y, Reisner (February 14, 2013). "Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells". Blood. 121 (7): 1220–1228. doi:10.1182/blood-2012-07-441493. PMC 4467899. PMID 23223359.
- ↑ Or-Geva, Noga; Gidron-Budovsky, Rotem; Sidlik-Muskatel, Rakefet; Singh, Aloukick Kumar; Reisner, Yair (November 1, 2019). "Next-generation CD8 memory veto T cells directed against memory antigens". Leukemia. 33 (11): 2737–2741. doi:10.1038/s41375-019-0501-1. PMID 31189891 – via PubMed. Unknown parameter
|s2cid=ignored (help) - ↑ Sidlik-Muskatel, Rakefet; Reisner, Yair (August 1, 2019). "Toward safer haploidnetical hematopoietic stem cell transplantation". Bone Marrow Transplantation. 54 (Suppl 2): 733–737. doi:10.1038/s41409-019-0595-0. PMID 31431713 – via PubMed. Unknown parameter
|s2cid=ignored (help) - ↑ Or-Geva, Noga; Reisner, Yair (March 1, 2016). "The evolution of T-cell depletion in haploidentical stem-cell transplantation". British Journal of Haematology. 172 (5): 667–684. doi:10.1111/bjh.13868. PMID 26684279 – via PubMed. Unknown parameter
|s2cid=ignored (help) - ↑ Rosen, Chava; Shezen, Elias; Aronovich, Anna; Klionsky, Yael Zlotnikov; Yaakov, Yasmin; Assayag, Miri; Biton, Inbal Eti; Tal, Orna; Shakhar, Guy; Ben-Hur, Herzel; Shneider, David; Vaknin, Zvi; Sadan, Oscar; Evron, Shmuel; Freud, Enrique; Shoseyov, David; Wilschanski, Michael; Berkman, Neville; Fibbe, Willem E; Hagin, David; Hillel-Karniel, Carmit; Krentsis, Irit Milman; Bachar-Lustig, Esther; Reisner, Yair (August 2015). "Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice". Nature Medicine. 21 (8): 869–879. doi:10.1038/nm.3889. PMID 26168294. Unknown parameter
|s2cid=ignored (help) - ↑ Milman Krentsis, Irit; Rosen, Chava; Shezen, Elias; Aronovich, Anna; Nathanson, Bar; Bachar-Lustig, Esther; Berkman, Neville; Assayag, Miri; Shakhar, Guy; Feferman, Tali; Orgad, Ran; Reisner, Yair (January 1, 2018). "Lung Injury Repair by Transplantation of Adult Lung Cells Following Preconditioning of Recipient Mice". Stem Cells Translational Medicine. 7 (1): 68–77. doi:10.1002/sctm.17-0149. PMC 5746155. PMID 29266820.
- ↑ Hillel-Karniel, Carmit; Rosen, Chava; Milman-Krentsis, Irit; Orgad, Ran; Bachar-Lustig, Esther; Shezen, Elias; Reisner, Yair (January 21, 2020). "Multi-lineage Lung Regeneration by Stem Cell Transplantation across Major Genetic Barriers". Cell Reports. 30 (3): 807–819.e4. doi:10.1016/j.celrep.2019.12.058. PMID 31968255 – via PubMed. Unknown parameter
|s2cid=ignored (help)
External links[edit]
- Yair Reisner on the ResearchGate website
- Personal page and CV on the Israel National Academy of Sciences website
- Interview, EMET prize website
- Interview, Weizmann Institute website
- Interview with Professor Yair Reisner, winner of the Rappaport Prize (2014) for an established Israeli researcher on YouTube
This article "Yair Reisner" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Yair Reisner. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
